{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:45:09Z","timestamp":1792903509013,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>MRI has a central role in the diagnosis and management of prostate cancer, including active surveillance (AS) of low- and favourable intermediate-risk cancer. Robust evidence supports its use to guide biopsies and stratify the risk of progression at the inclusion stage. The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) criteria provide the foundation for standardised assessment on serial imaging during AS. Despite potential reductions in the number of unnecessary follow-up biopsies, uncertainty about the degree to which follow-up strategies can be defined by MRI leads to variation in international guidelines and their implementation. Here, the European Society of Urogenital Radiology (ESUR)\u2013Prostate MRI Working Group reviews the evidence for the use of MRI in AS and provides practical guidance on its use. Additional research is needed to personalise AS strategies by integrating patient-specific factors, including family history and ethnicity, as well as emerging biomarkers such as genomic profiling and technological innovations like artificial intelligence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical relevance statement<\/jats:title>\n                    <jats:p>MRI is an integral part of AS, and initiatives to standardise image acquisition and reporting are underway. Further research is needed to better define MRI\u2019s role during follow-up and to personalise AS, which could help achieve better harmonisation among international guidelines. The European Society of Urogenital Radiology (ESUR) prostate working group provides suggestions for practical implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient summary<\/jats:title>\n                    <jats:p>Active surveillance is a safe and effective management strategy for indolent prostate cancer. It avoids complications associated with surgery and radiation treatment. MRI has a central role in selecting which patients will benefit most from active surveillance and helping choose the most appropriate follow-up strategy. Acquiring standardised images and using reporting systems like PRECISE improves prostate cancer assessment and may help reduce the number of unnecessary biopsies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>MRI plays a central role during active surveillance, but its implementation varies widely across centres.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This ESUR position statement offers practical guidance on MRI acquisition, reporting, and interpretation tailored to active surveillance.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Use of MRI\u2014including the PRECISE score for active surveillance and the PI-QUAL score for image quality\u2014can improve consistency and accuracy in monitoring prostate cancer over time.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-026-02245-0","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T10:27:08Z","timestamp":1775125628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["European Society of Urogenital Radiology (ESUR) perspectives on the role of prostate MRI in active surveillance"],"prefix":"10.1186","volume":"17","author":[{"given":"Stephan","family":"Ursprung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo H.","family":"Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refky","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"De Visschere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Yakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-6431","authenticated-orcid":false,"given":"Francesco","family":"Giganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Asbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the\u00a0ESUR Prostate MRI Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2245_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","volume":"10","author":"T Fazekas","year":"2024","unstructured":"Fazekas T, Shim SR, Basile G et al (2024) Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis. JAMA Oncol 10:745\u2013754","journal-title":"JAMA Oncol"},{"key":"2245_CR2","doi-asserted-by":"publisher","unstructured":"Schoots IG, Haider MA, Punwani S, Padhani AR (2025) MRI in prostate cancer screening: a review and recommendations, from the AJR Special Series on Screening. AJR Am J Roentgenol. https:\/\/doi.org\/10.2214\/AJR.24.32588","DOI":"10.2214\/AJR.24.32588"},{"key":"2245_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2025.05.038","volume":"88","author":"IG Schoots","year":"2025","unstructured":"Schoots IG, Ahmed HU, Albers P et al (2025) Magnetic resonance imaging-based biopsy strategies in prostate cancer screening: a systematic review. Eur Urol 88:247\u2013260","journal-title":"Eur Urol"},{"key":"2245_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","volume":"77","author":"FH Drost","year":"2020","unstructured":"Drost FH, Osses D, Nieboer D et al (2020) Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis. Eur Urol 77:78\u201394","journal-title":"Eur Urol"},{"key":"2245_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.eururo.2020.04.029","volume":"78","author":"JM Norris","year":"2020","unstructured":"Norris JM, Carmona Echeverria LM, Bott SRJ et al (2020) What type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? An analysis from the PROMIS Cohort. Eur Urol 78:163\u2013170","journal-title":"Eur Urol"},{"key":"2245_CR6","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.euf.2023.10.006","volume":"10","author":"F Pellegrino","year":"2024","unstructured":"Pellegrino F, Stabile A, Sorce G et al (2024) Added value of prostate-specific antigen density in selecting prostate biopsy candidates among men with elevated prostate-specific antigen and PI-RADS \u22653 lesions on multiparametric magnetic resonance imaging of the prostate: a systematic assessment by PI-RADS score. Eur Urol Focus 10:634\u2013640","journal-title":"Eur Urol Focus"},{"key":"2245_CR7","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ijc.29538","volume":"137","author":"KJ Bell","year":"2015","unstructured":"Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P (2015) Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer 137:1749\u20131757","journal-title":"Int J Cancer"},{"key":"2245_CR8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA et al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 388:1547\u20131558","journal-title":"N Engl J Med"},{"key":"2245_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","volume":"77","author":"L Klotz","year":"2020","unstructured":"Klotz L, Pond G, Loblaw A et al (2020) Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur Urol 77:311\u2013317","journal-title":"Eur Urol"},{"key":"2245_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clgc.2020.06.008","volume":"19","author":"W Baccaglini","year":"2021","unstructured":"Baccaglini W, Glina FA, Pazeto CL et al (2021) Accuracy of MRI-guided versus systematic prostate biopsy in patients under active surveillance: a systematic review and meta-analysis. Clin Genitourin Cancer 19:3\u201311.e11","journal-title":"Clin Genitourin Cancer"},{"key":"2245_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","volume":"80","author":"P Rajwa","year":"2021","unstructured":"Rajwa P, Pradere B, Quhal F et al (2021) Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis. Eur Urol 80:549\u2013563","journal-title":"Eur Urol"},{"key":"2245_CR12","unstructured":"Ahmed HU et al (2025) Imperial Prostate 9\u2014ATLAS (aproaches to long-term active surveillance) (IP9-ATLAS). Available via https:\/\/ichgcp.net\/clinical-trials-registry\/NCT06280781. Accessed 4 Aug 2025"},{"key":"2245_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","volume":"76","author":"TBL Lam","year":"2019","unstructured":"Lam TBL, MacLennan S, Willemse PM et al (2019) EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study). Eur Urol 76:790\u2013813","journal-title":"Eur Urol"},{"key":"2245_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/his.13712","volume":"74","author":"A Matoso","year":"2019","unstructured":"Matoso A, Epstein JI (2019) Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology 74:135\u2013145","journal-title":"Histopathology"},{"key":"2245_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","volume":"271","author":"JI Epstein","year":"1994","unstructured":"Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368\u2013374","journal-title":"JAMA"},{"key":"2245_CR16","doi-asserted-by":"publisher","first-page":"e1002063","DOI":"10.1371\/journal.pmed.1002063","volume":"13","author":"VJ Gnanapragasam","year":"2016","unstructured":"Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC (2016) Improving clinical risk stratification at diagnosis in primary prostate cancer: a prognostic modelling study. PLoS Med 13:e1002063","journal-title":"PLoS Med"},{"key":"2245_CR17","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/jnci\/dji248","volume":"97","author":"PC Albertsen","year":"2005","unstructured":"Albertsen PC, Hanley JA, Barrows GH et al (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248\u20131253","journal-title":"J Natl Cancer Inst"},{"key":"2245_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/PAS.0000000000000723","volume":"41","author":"JB Gordetsky","year":"2017","unstructured":"Gordetsky JB, Thomas JV, Nix JW, Rais-Bahrami S (2017) Higher prostate cancer grade groups are detected in patients undergoing multiparametric MRI-targeted biopsy compared with standard biopsy. Am J Surg Pathol 41:101\u2013105","journal-title":"Am J Surg Pathol"},{"key":"2245_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.eururo.2021.06.026","volume":"80","author":"AJ Vickers","year":"2021","unstructured":"Vickers AJ (2021) Effects of magnetic resonance imaging targeting on overdiagnosis and overtreatment of prostate cancer. Eur Urol 80:567\u2013572","journal-title":"Eur Urol"},{"key":"2245_CR20","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","volume":"70","author":"RA Godtman","year":"2016","unstructured":"Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J (2016) Long-term results of active surveillance in the Goteborg randomized, population-based prostate cancer screening trial. Eur Urol 70:760\u2013766","journal-title":"Eur Urol"},{"key":"2245_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","volume":"5","author":"M Baboudjian","year":"2022","unstructured":"Baboudjian M, Breda A, Rajwa P et al (2022) Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression. Eur Urol Oncol 5:617\u2013627","journal-title":"Eur Urol Oncol"},{"key":"2245_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.euo.2024.07.003","volume":"8","author":"C Bangma","year":"2025","unstructured":"Bangma C, Doan P, Zhu L et al (2025) Has active surveillance for prostate cancer become safer? Lessons learned from a global clinical registry. Eur Urol Oncol 8:324\u2013337","journal-title":"Eur Urol Oncol"},{"key":"2245_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-023-01315-5","volume":"23","author":"G Gandaglia","year":"2023","unstructured":"Gandaglia G, Leni R, Plagakis S, Stabile A, Montorsi F, Briganti A (2023) Active surveillance should not be routinely considered in ISUP Grade Group 2 prostate cancer. BMC Urol 23:153","journal-title":"BMC Urol"},{"key":"2245_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.euros.2021.08.016","volume":"38","author":"F Giganti","year":"2022","unstructured":"Giganti F, Stavrinides V, Moore CM (2022) Magnetic resonance imaging-guided active surveillance of prostate cancer: time to say goodbye to protocol-based biopsies. Eur Urol Open Sci 38:40\u201343","journal-title":"Eur Urol Open Sci"},{"key":"2245_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.eururo.2021.12.007","volume":"81","author":"PM Willemse","year":"2022","unstructured":"Willemse PM, Davis NF, Grivas N et al (2022) Systematic review of active surveillance for clinically localised prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy. Eur Urol 81:337\u2013346","journal-title":"Eur Urol"},{"key":"2245_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.juro.2017.10.010","volume":"199","author":"F Audenet","year":"2018","unstructured":"Audenet F, Vertosick EA, Fine SW et al (2018) Biopsy core features are poor predictors of adverse pathology in men with Grade Group 1 prostate cancer. J Urol 199:961\u2013968","journal-title":"J Urol"},{"key":"2245_CR27","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Mediyinischen Fachgesellschaften (2025) S3-Leitlinie prostatakarzinom. Arbeitsgemeinschaft der Wissenschaftlichen Mediyinischen Fachgesellschaften, Berlin"},{"key":"2245_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41391-021-00425-1","volume":"25","author":"HT Vigneswaran","year":"2022","unstructured":"Vigneswaran HT, Mittelstaedt L, Crippa A et al (2022) Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 25:165\u2013173","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2245_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.euros.2021.09.012","volume":"34","author":"K Beckmann","year":"2021","unstructured":"Beckmann K, Santaolalla A, Helleman J et al (2021) Comparison of characteristics, follow-up and outcomes of active surveillance for prostate cancer according to ethnicity in the GAP3 Global Consortium Database. Eur Urol Open Sci 34:47\u201354","journal-title":"Eur Urol Open Sci"},{"key":"2245_CR30","doi-asserted-by":"crossref","unstructured":"Hagmann S, Ramakrishnan V, Tamalunas A et al (2022) Two decades of active surveillance for prostate cancer in a single-center cohort: favorable outcomes after transurethral resection of the prostate. Cancers (Basel) 14:368","DOI":"10.3390\/cancers14020368"},{"key":"2245_CR31","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/jso.23584","volume":"109","author":"FB Thomsen","year":"2014","unstructured":"Thomsen FB, Brasso K, Klotz LH, Roder MA, Berg KD, Iversen P (2014) Active surveillance for clinically localized prostate cancer\u2014a systematic review. J Surg Oncol 109:830\u2013835","journal-title":"J Surg Oncol"},{"key":"2245_CR32","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/bju.14987","volume":"125","author":"RJ Bryant","year":"2020","unstructured":"Bryant RJ, Oxley J, Young GJ et al (2020) The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU Int 125:506\u2013514","journal-title":"BJU Int"},{"key":"2245_CR33","doi-asserted-by":"publisher","unstructured":"Sushentsev N, Li IG, Xu G et al (2025) Predicting active surveillance failure for patients with prostate cancer in the magnetic resonance imaging era: a multicentre transatlantic cohort study. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2025.06.012","DOI":"10.1016\/j.euo.2025.06.012"},{"key":"2245_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/jamaoncol.2024.5497","volume":"11","author":"CA Hamm","year":"2025","unstructured":"Hamm CA, Asbach P, Pohlmann A et al (2025) Oncological safety of MRI-informed biopsy decision-making in men with suspected prostate cancer. JAMA Oncol 11:145\u2013153","journal-title":"JAMA Oncol"},{"key":"2245_CR35","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.23.29969","volume":"223","author":"N Tan","year":"2024","unstructured":"Tan N, Pollock JR, Margolis DJA et al (2024) Management of patients with a negative multiparametric prostate MRI examination: AJR Expert Panel Narrative Review. AJR Am J Roentgenol 223:e2329969","journal-title":"AJR Am J Roentgenol"},{"key":"2245_CR36","doi-asserted-by":"crossref","unstructured":"Lanzotti NJ, Du C, Hall J, Saba J, Picken MM, Gupta GN (2025) Comparing multigene molecular testing results of MRI-target versus systematic prostate needle biopsies of candidates for and under active surveillance. J Pers Med 15:279","DOI":"10.3390\/jpm15070279"},{"key":"2245_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrurol.2017.26","volume":"14","author":"SM Bruinsma","year":"2017","unstructured":"Bruinsma SM, Roobol MJ, Carroll PR et al (2017) Expert consensus document: semantics in active surveillance for men with localized prostate cancer\u2014results of a modified Delphi consensus procedure. Nat Rev Urol 14:312\u2013322","journal-title":"Nat Rev Urol"},{"key":"2245_CR38","doi-asserted-by":"publisher","unstructured":"Tohi Y, Yokomizo A, Matsumoto R et al (2025) Temporal changes in the urologist\u2019s practice behaviour of active surveillance for prostate cancer: analysis of prospective observational study cohort. Jpn J Clin Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyaf102","DOI":"10.1093\/jjco\/hyaf102"},{"key":"2245_CR39","doi-asserted-by":"crossref","unstructured":"Nasseri P, Veldwijk J, Niehot C et al (2025) Key determinants influencing treatment decision-making for and adherence to active surveillance for prostate cancer: a systematic review. J Pers Med 15:315","DOI":"10.3390\/jpm15070315"},{"key":"2245_CR40","doi-asserted-by":"publisher","first-page":"40103","DOI":"10.57187\/smw.2023.40103","volume":"153","author":"C Poyet","year":"2023","unstructured":"Poyet C, Scherer TP, Kunz M et al (2023) Retrospective analysis of the uptake of active surveillance for low-risk prostate cancer in Zurich, Switzerland. Swiss Med Wkly 153:40103","journal-title":"Swiss Med Wkly"},{"key":"2245_CR41","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.euo.2019.05.005","volume":"3","author":"H Olsson","year":"2020","unstructured":"Olsson H, Nordstrom T, Clements M, Gronberg H, Lantz AW, Eklund M (2020) Intensity of active surveillance and transition to treatment in men with low-risk prostate cancer. Eur Urol Oncol 3:640\u2013647","journal-title":"Eur Urol Oncol"},{"key":"2245_CR42","unstructured":"Nationella prostatacancerregistret (NPCR) (2025). Interactive prostate cancer report. Available via https:\/\/statistik.incanet.se\/npcr\/. Accessed 4 Aug 2025"},{"key":"2245_CR43","unstructured":"Institute for Quality and Efficiency in Healthcare (2020) Prostate cancer screening with a PSA test. Institute for Quality and Efficiency in Healthcare, Cologne, Germany"},{"key":"2245_CR44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.euo.2020.09.002","volume":"4","author":"D Hettiarachchi","year":"2021","unstructured":"Hettiarachchi D, Geraghty R, Rice P et al (2021) Can the use of serial multiparametric magnetic resonance imaging during active surveillance of prostate cancer avoid the need for prostate biopsies? A systematic diagnostic test accuracy review. Eur Urol Oncol 4:426\u2013436","journal-title":"Eur Urol Oncol"},{"key":"2245_CR45","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.eururo.2015.06.012","volume":"68","author":"LP Bokhorst","year":"2015","unstructured":"Bokhorst LP, Alberts AR, Rannikko A et al (2015) Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol 68:814\u2013821","journal-title":"Eur Urol"},{"key":"2245_CR46","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","volume":"71","author":"CM Moore","year":"2017","unstructured":"Moore CM, Giganti F, Albertsen P et al (2017) Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations\u2014a report of a European School of Oncology Task Force. Eur Urol 71:648\u2013655","journal-title":"Eur Urol"},{"key":"2245_CR47","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","volume":"86","author":"C Englman","year":"2024","unstructured":"Englman C, Maffei D, Allen C et al (2024) PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer. Eur Urol 86:240\u2013255","journal-title":"Eur Urol"},{"key":"2245_CR48","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1007\/s00330-024-10795-4","volume":"34","author":"M de Rooij","year":"2024","unstructured":"de Rooij M, Allen C, Twilt JJ et al (2024) PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol 34:7068\u20137079","journal-title":"Eur Radiol"},{"key":"2245_CR49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euros.2023.10.005","volume":"59","author":"B Valentin","year":"2024","unstructured":"Valentin B, Arsov C, Ullrich T et al (2024) Magnetic resonance imaging-guided active surveillance without annual rebiopsy in patients with Grade Group 1 or 2 prostate cancer: the prospective PROMM-AS Study. Eur Urol Open Sci 59:30\u201338","journal-title":"Eur Urol Open Sci"},{"key":"2245_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.euros.2023.08.006","volume":"56","author":"J Aerts","year":"2023","unstructured":"Aerts J, Hendrickx S, Berquin C et al (2023) Clinical application of the prostate cancer radiological estimation of change in sequential evaluation score for reporting magnetic resonance imaging in men on active surveillance for prostate cancer. Eur Urol Open Sci 56:39\u201346","journal-title":"Eur Urol Open Sci"},{"key":"2245_CR51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.euo.2022.03.007","volume":"5","author":"HB Luiting","year":"2022","unstructured":"Luiting HB, Remmers S, Boeve ER et al (2022) A multivariable approach using magnetic resonance imaging to avoid a protocol-based prostate biopsy in men on active surveillance for prostate cancer\u2014data from the international multicenter prospective PRIAS Study. Eur Urol Oncol 5:651\u2013658","journal-title":"Eur Urol Oncol"},{"key":"2245_CR52","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","volume":"78","author":"V Stavrinides","year":"2020","unstructured":"Stavrinides V, Giganti F, Trock B et al (2020) Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study. Eur Urol 78:443\u2013451","journal-title":"Eur Urol"},{"key":"2245_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.euo.2023.01.003","volume":"6","author":"CM Moore","year":"2023","unstructured":"Moore CM, King LE, Withington J et al (2023) Best current practice and research priorities in active surveillance for prostate cancer\u2014a report of a Movember International Consensus Meeting. Eur Urol Oncol 6:160\u2013182","journal-title":"Eur Urol Oncol"},{"key":"2245_CR54","doi-asserted-by":"publisher","first-page":"e2445505","DOI":"10.1001\/jamanetworkopen.2024.45505","volume":"7","author":"SR Stock","year":"2024","unstructured":"Stock SR, Burns MT, Waller J et al (2024) Racial and ethnic differences in prostate cancer epidemiology across disease states in the VA. JAMA Netw Open 7:e2445505","journal-title":"JAMA Netw Open"},{"key":"2245_CR55","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/UPJ.0000000000000529","volume":"11","author":"SP Basourakos","year":"2024","unstructured":"Basourakos SP, An A, Davuluri M et al (2024) Racial and ethnic variation in receipt and intensity of active surveillance for older patients with localized prostate cancer. Urol Pract 11:538\u2013546","journal-title":"Urol Pract"},{"key":"2245_CR56","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2214\/AJR.23.29518","volume":"221","author":"N Sanmugalingam","year":"2023","unstructured":"Sanmugalingam N, Sushentsev N, Lee KL et al (2023) The PRECISE recommendations for prostate MRI in patients on active surveillance for prostate cancer: a critical review. AJR Am J Roentgenol 221:649\u2013660","journal-title":"AJR Am J Roentgenol"},{"key":"2245_CR57","doi-asserted-by":"publisher","first-page":"7716","DOI":"10.1007\/s00330-024-10863-9","volume":"34","author":"AB Dias","year":"2024","unstructured":"Dias AB, Woo S, Leni R et al (2024) Is MRI ready to replace biopsy during active surveillance? Eur Radiol 34:7716\u20137727","journal-title":"Eur Radiol"},{"key":"2245_CR58","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.240078","volume":"7","author":"C Roest","year":"2025","unstructured":"Roest C, Kwee TC, de Jong IJ et al (2025) Development and validation of a deep learning model based on MRI and clinical characteristics to predict risk of prostate cancer progression. Radiol Imaging Cancer 7:e240078","journal-title":"Radiol Imaging Cancer"},{"key":"2245_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: Screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163","journal-title":"Eur Urol"},{"key":"2245_CR60","unstructured":"Cancer Council Australia (2020) Clinical practice guidelines for PSA testing and early management of test-detected prostate cancer. Cancer Council Australia. Available via https:\/\/www.cancer.org.au\/health-professionals\/clinical-practice-guidelines\/psa-testing"},{"key":"2245_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-01036-1","volume":"22","author":"ML Wroclawski","year":"2022","unstructured":"Wroclawski ML, Amaral BS, Kayano PP et al (2022) Knowledge, attitudes, and practices of active surveillance in prostate cancer among urologists: a real-life survey from Brazil. BMC Urol 22:86","journal-title":"BMC Urol"},{"key":"2245_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2024.102717","volume":"34","author":"G Ploussard","year":"2024","unstructured":"Ploussard G, Baboudjian M, Barret E et al (2024) French AFU Cancer Committee Guidelines\u2014update 2024\u20132026: prostate cancer\u2014diagnosis and management of localised disease. Fr J Urol 34:102717","journal-title":"Fr J Urol"},{"key":"2245_CR63","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bju.16436","volume":"134","author":"T Kato","year":"2024","unstructured":"Kato T, Matsumoto R, Yokomizo A et al (2024) Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN). BJU Int 134:652\u2013658","journal-title":"BJU Int"},{"key":"2245_CR64","doi-asserted-by":"crossref","unstructured":"van den Bergh RCN, Roemeling S, Roobol MJ et al (2007) Prospective Validation of Active Surveillance in Prostate Cancer: The PRIAS Study. Eur Urol 52:1560\u20131563","DOI":"10.1016\/j.eururo.2007.05.011"},{"key":"2245_CR65","unstructured":"Anderson D, Barnes R, Bida M et al (2017) South African prostate cancer guidelines\u2014draft Version 2017. Available via https:\/\/prostate-ca.co.za\/wp-content\/uploads\/2017ProstateGuidelinesDraftVersion2016.pdf"},{"key":"2245_CR66","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5534\/wjmh.210163","volume":"41","author":"G Jung","year":"2023","unstructured":"Jung G, Kim JK, Jeon SS et al (2023) Establishment of prospective registry of active surveillance for prostate cancer: the Korean Urological Oncology Society Database. World J Mens Health 41:110\u2013118","journal-title":"World J Mens Health"},{"key":"2245_CR67","unstructured":"National Institute for Health and Care Excellence (2021). Prostate cancer: diagnosis and management. National Institute for Health and Care Excellence. Available via https:\/\/www.nice.org.uk\/guidance\/NG131"},{"key":"2245_CR68","unstructured":"National Comprehensive Cancer Network (2025) Prostate cancer. NCCN clinical practice guidelines in oncology, 1.2026. National Comprehensive Cancer Network. Available via https:\/\/www.nccn.org\/guidelines\/guidelines-detail?%20category=1&id=1459"},{"key":"2245_CR69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA et al (2022) Clinically localized prostate cancer: AUA\/ASTRO guideline, Part II: Principles of active surveillance, principles of surgery, and follow-up. J Urol 208:19\u201325","journal-title":"J Urol"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-026-02245-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:02:53Z","timestamp":1775127773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-026-02245-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2245"],"URL":"https:\/\/doi.org\/10.1186\/s13244-026-02245-0","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.A. reports consulting fees from the Professional Association of the German Radiologist (BDR e.\u200aV.). F.G. reports consulting fees from DeepHealth, SpectraCure and Procept outside of the submitted work. He has received speaker fees from Bayer and Siemens. None of the other authors report any competing interest in relation to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}